Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping ...

A new study found weight loss injections may help reduce the risk of dementia and stroke in people who are obese and have ...

In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...

A new scientific study has found that weight loss jabs such as Mounjaro and Ozempic can help protect against serious health issues like dementia ...

Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment <li /> Combination of oral PL7737 ...